20 completed, 9 recruiting, 4 unknown, 2 terminated. 18 Phase 3, 11 Phase 2, 3 Not applicable, 3 Phase 1, 1 Early Phase 1.
Follow Agammaglobulinemia: new trials by email Literature Review of Agammaglobulinemia trials Research Report on Agammaglobulinemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM Busulfan, Palifermin, Plerixafor - WHIM, Warts | Phase 1 / Phase 2 | Enrolling by invitation | National Institute of Allergy and Infectious Diseases (NIAID) | 10 | 2026-10-27 | 2026-10-22 |
| Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies IgPro20 - Secondary Immune Deficiency | Phase 3 | Recruiting | CSL Behring | 63 | 2026-09-15 | 2026-10-14 |
| Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections Panzyga, 10% Intravenous Solution, Placebo - Hypogammaglobulinemia, Autoimmune Conditions | Phase 3 | Recruiting | Octapharma | 360 | 2026-06-10 | 2026-09-29 |
| V-IMMUNE: A Novel Immunoglobulin Therapy for Immunodeficiency Intravenous immunoglobulin (IVIG) - Immunodeficiencies, Primary Immunodeficiencies (PID) | Phase 3 | Recruiting | On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA. | 50 | 2025-08-15 | 2026-01-20 |
| Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia IgPro20 - Multiple Myeloma, Hypogammaglobulinemia | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 100 | 2025-05-08 | 2026-10-05 |
| A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma Xembify, Placebo - Hypogammaglobulinemia, Bacterial Infections | Phase 3 | Recruiting | Grifols Therapeutics LLC | 386 | 2022-12-26 | 2026-09-30 |
| Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension trimethoprim-sulfamethoxazole (co-trimoxazole), amoxycillin/clavulanic acid and ciprofloxacin, Immunoglobulins - Haematological Malignancy, Hypogammaglobulinemia | Phase 2 / Phase 3 | Recruiting | Monash University | 300 | 2022-11-30 | 2024-04-19 |
| IVIG vs SCIG in CIDP Intravenous immune globulin G, Subcutaneous immune globulin G - CIDP, Immunoglobulin Deficiency | Phase 1 | Recruiting | Rutgers, The State University of New Jersey | 20 | 2022-09-11 | 2025-12-11 |
| Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)? Laboratory test - Hypogammaglobulinemia, Multiple Sclerosis | Recruiting | Insel Gruppe AG, University Hospital Bern | 106 | 2022-07-01 | 2026-05-01 | |
| Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10) Kedrion IVIG 10% - Primary Immunodeficiency Disease | Phase 3 | Active not recruiting | Kedrion S.p.A. | 30 | 2021-03-31 | 2026-05-29 |
| Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study) Panzyga, Placebo - Chronic Lymphocytic Leukemia, Hypogammaglobulinemia | Phase 3 | Completed | Octapharma | 247 | 2020-10-05 | 2026-06-04 |
| Immunodeficiency in MS No Interventions - Multiple Sclerosis, Hypogammaglobulinemia | Unknown | Advanced Neurosciences Institute | 1500 | 2020-06-29 | 2020-06-25 | |
| Rituximab-Induced Hypogammaglobulinemia in Multiple Sclerosis Serum immunoglobulin titer - Multiple Sclerosis, Hypogammaglobulinemia | Unknown | Mazandaran University of Medical Sciences | 170 | 2020-02-28 | 2020-07-10 | |
| Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients Kedrion IVIG 10% - Primary Immunodeficiency Disease | Phase 3 | Completed | Kedrion S.p.A. | 47 | 2019-04-30 | 2026-05-05 |
| A Retrospective and Prospective Natural History Study of Patients With WHIM Syndrome No intervention - WHIM Syndrome | Withdrawn | X4 Pharmaceuticals | 2018-06-01 | 2018-12-07 | ||
| Oral Colostrum and Its Effect on Immune System Orally Colostrum - Immune System Diseases, Premature Infant Disease | Phase 3 | Unknown | Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes | 96 | 2018-06-01 | 2019-10-02 |
| Subcutaneous Ig in Allogeneic Stem Cell Transplant Recipients subcutaneous immunoglobulin - Hypogammaglobulinemia | Not applicable | Completed | University Health Network, Toronto | 20 | 2018-02-01 | 2019-05-09 |
| Personalized Immunotherapeutic for Antibiotic-resistant Infection anti-mycoplasma hominis antibodies - Infection, Immune Deficiency | Early Phase 1 | Completed | Brigham and Women's Hospital | 1 | 2016-04-12 | 2020-01-18 |
| Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL) Lenalidomide, Influenza Vaccine, Pneumovax Vaccine - Hematologic Disorder | Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2014-11-24 | 2018-09-20 |
| Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome Plerixafor, G-CSF - Myelokathexis, Infections | Phase 2 / Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 20 | 2014-10-14 | 2026-06-26 |
Showing 20 of 38. Sign in to see all of them.
Primary Immunodeficiency Diseases (11) · Common Variable Immunodeficiency (9) · Immunologic Deficiency Syndromes (8) · Infections (6) · Leukemia, Lymphocytic, Chronic, B-Cell (5) · Warts (4) · IgG Deficiency (3) · Multiple Sclerosis (3) · Neutropenia (3) · Bacterial Infections (2) · Fatigue (2) · Hematologic Neoplasms (2) · Multiple Myeloma (2) · Wiskott-Aldrich Syndrome (2)
Blood Protein Disorders (38) · Hemic and Lymphatic Diseases (38) · Lymphatic Diseases (38) · Lymphoproliferative Disorders (38) · Hematologic Diseases (37) · Immune System Diseases (37) · Immunologic Deficiency Syndromes (30) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (13) · Genetic Diseases, Inborn (11) · Pathological Conditions, Signs and Symptoms (9) · Pathologic Processes (8) · Disease Attributes (7) · Immunoproliferative Disorders (7) · Neoplasms by Histologic Type (7) · Chronic Disease (6)
Immunoglobulins, Intravenous (9) · gamma-Globulins (6) · Hizentra (3) · plerixafor (3) · Filgrastim (2) · Lenalidomide (2) · Panzyga (2) · Saline Solution (2) · Amoxicillin (1) · Busulfan (1) · Caprylates (1) · Ciprofloxacin (1) · Clavulanic Acid (1) · Clinical Laboratory Techniques (1) · Detergents (1)
CSL Behring (5) · National Institute of Allergy and Infectious Diseases (NIAID) (4) · Kedrion S.p.A. (3) · Grifols Therapeutics LLC (2) · M.D. Anderson Cancer Center (2) · Octapharma (2) · Advanced Neurosciences Institute (1) · Baxalta now part of Shire (1) · Bio Products Laboratory (1) · Brigham and Women's Hospital (1) · BriovaRx Infusion Services (1) · Columbia University (1) · Federal University of São Paulo (1) · Insel Gruppe AG, University Hospital Bern (1) · Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes (1)
United States (25) · Canada (5) · Italy (4) · Poland (4) · Germany (3) · Hungary (3) · Spain (3) · Brazil (2) · Bulgaria (2) · Czechia (2) · Denmark (2) · Greece (2) · Russia (2) · Australia (1) · Belgium (1)
David H McDermott, M.D. (2) · Albertina RB Pizzamiglio, md MSc (1) · Alessandra Ferrajoli (1) · Alessandra Ferrajoli, MD,BS (1) · Aparecida T Nagao-Dias (1) · Araceli Montoya-Estrada, PhD (1) · Beatriz T Costa Carvalho, md PhD (1) · Charles K Naspitz, md MSc (1) · Chiara Azzari (1) · Dewton Moraes Vasconcelos, PhD (1) · Diana M Soriano-Becerril, MSc (1) · Duane R. Wesemann, MD, PhD (1) · Erwin Gelfand, MD (1)
PMID 17479360, PMID 18814020, PMID 20217199, PMID 21890643, PMID 21932110, PMID 24523241, PMID 24723677, PMID 25090414, PMID 29272362, PMID 29358183, PMID 33684377, PMID 35874579, PMID 36818468, PMID 37561579, PMID 40330596, PMID 42105146, PMID 42606118
P30CA016672 (1)